Clinical Trial

A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The study will consist of a Phase I dose-escalation and Phase IIa dose-expansion component. Phase I dose-escalation phase will establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D),and evaluate the preliminary antitumor activity of HX111.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-30.
Trial Details
NCT Number NCT07333469
Lead Sponsor Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Conditions Solid Tumor and Lymphoma
Enrollment 70 participants
Start Date 2026-01-19
Primary Completion 2028-01-19 (estimated)
Study Completion 2030-01-19 (estimated)
Updated on ClinicalTrials.gov 2026-01-13